Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01495988
Title Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Melanoma Research Foundation Breakthrough Consortium
Indications

melanoma

Therapies

Bevacizumab

Vemurafenib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
The Angeles Clinic Los Angeles California 90025 United States Details
University of Colorado Cancer Center Aurora Colorado 80045 United States Details
Georgetown Lombardi Comprehensive Cancer Center Washington, D.C. District of Columbia 20007 United States Details
Washington Cancer Institute at MedStar Washington Hospital Center Washington, D.C. District of Columbia 20010 United States Details
Harry and Jeannette Weinberg Cancer Institute at Franklin Square Baltimore Maryland 21237 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center (BIDMC) Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
NYU Clinical Cancer Center New York New York 10016 United States Details
Columbia University Medical Center New York New York 10032 United States Details
OSU Comprehensive Cancer Center Columbus Ohio 43210 United States Details
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 United States Details
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232 United States Details
University of Washington Medical Center Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field